2. Metabolic Enzyme/Protease Immunology/Inflammation
  3. Dihydroorotate Dehydrogenase Interleukin Related FXR
  4. Vidofludimus

Vidofludimus  (Synonyms: 4sc-101; SC12267)

Cat. No.: HY-14908 Purity: 99.11%
COA Handling Instructions

Molarity Calculator

Vidofludimus is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus also can be used for the research of fatty liver by targeting FXR.

For research use only. We do not sell to patients.

Vidofludimus Chemical Structure

Vidofludimus Chemical Structure

CAS No. : 717824-30-1

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 77 In-stock
Solution
10 mM * 1 mL in DMSO USD 77 In-stock
Solid
5 mg USD 99 In-stock
10 mg USD 165 In-stock
50 mg USD 495 In-stock
100 mg USD 704 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Vidofludimus:

Vidofludimus Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Vidofludimus

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Vidofludimus is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus also can be used for the research of fatty liver by targeting FXR[1][2][3].

IC50 & Target[1][2]

IL-17

 

In Vitro

Vidofludimus (0-1 µM) selectively activats FXR in a concentration dependent manner with an EC50 value of about 450 nM in inducing the recruitment of various coactivator LXXLL motifs[1].
Vidofludimus (0-8 μM) blocks nuclear translocation of p65 by suppressing IKK-IκB-NF-κB pathway[1].
Vidofludimus has inhibitory activity for human DHODH with an IC50 value of 160 nM[2].
Vidofludimus inhibits dihydro-orotate dehydrogenase and lymphocyte proliferation in vitro[3].
Vidofludimus inhibits interleukin (IL)-17 secretion in vitro independently of effects on lymphocyte proliferation[3].
Vidofludimus completely blocks IL-23 + IL-1β-stimulated secretion of IL-17 by colonic strips in ex vivo[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Vidofludimus Related Antibodies

Western Blot Analysis[1]

Cell Line: HepG2 cells or MEFs
Concentration: 2, 8 μM
Incubation Time: 1 h
Result: Inhibited of TNFα-induced IKKα/β phosphorylation and IκBα degradation.

RT-PCR[1]

Cell Line: HepG2 cells
Concentration: 5 μM
Incubation Time: 24 h
Result: Inhibited the increase of NF-κB target genes MCP-1 and CXCL-2 upon TNFα stimulation.
In Vivo

Vidofludimus (i.p.; once daily; for 14 days) exerts effects on dextran sodium sulfate (DSS) induced colitis in an FXR-dependent manner in vivo[1].
Vidofludimus (p.o; 60 mg/kg; for 6 days) effectively improves many parameters of TNBS-induced colitis in rats and has inhibitory effects on colonic STAT3 and IL-17[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: homozygous FXR deficient (FXR KO) mice[1]
(10-week-old, male)
Dosage: 20 mg/kg
Administration: oral, 20 mg/kg/day
Result: Revealed multifocal inflammatory cell infiltration and edema with crypt and epithelial cell destruction and ulceration.
Animal Model: NAFLD Model[1]
(10-11 weeks old male obese Lepob/ob C57BL/6 (ob/ob) mice)
Dosage: 10 mg/kg
Administration: intraperitoneally, once daily, for 14 days
Result: Significantly reduced body weight loss, prevented colonic shortening, decreased histological scores, and disease activity index (DAI) scores in WT mice.
Significantly decreased colonic mRNA expression of the pro-inflammatorygenes interleukin (IL)-1β, IL-6, IL-17, and prostaglandin-endoperoxide synthase 2 (COX-2).
Animal Model: Wistar rats[3]
Dosage: 60 mg/kg
Administration: p.o., for 6 days
Result: Effectively reduced macroscopic and histological pathology and the numbers of CD3+ T cells in vivo.
Reduced nuclear signal transducer and activator of transcription 3 (STAT3) binding and IL-17 levels.
Clinical Trial
Molecular Weight

355.36

Formula

C20H18FNO4
CAS No.
Appearance

Solid

Color

Light yellow to gray

SMILES

O=C(C1=C(C(NC2=CC=C(C3=CC=CC(OC)=C3)C=C2F)=O)CCC1)O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : ≥ 46 mg/mL (129.45 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.8140 mL 14.0702 mL 28.1405 mL
5 mM 0.5628 mL 2.8140 mL 5.6281 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: 2.5 mg/mL (7.04 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.5 mg/mL (7.04 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.11%

COA (250 KB) LCMS (93 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.8140 mL 14.0702 mL 28.1405 mL 70.3512 mL
5 mM 0.5628 mL 2.8140 mL 5.6281 mL 14.0702 mL
10 mM 0.2814 mL 1.4070 mL 2.8140 mL 7.0351 mL
15 mM 0.1876 mL 0.9380 mL 1.8760 mL 4.6901 mL
20 mM 0.1407 mL 0.7035 mL 1.4070 mL 3.5176 mL
25 mM 0.1126 mL 0.5628 mL 1.1256 mL 2.8140 mL
30 mM 0.0938 mL 0.4690 mL 0.9380 mL 2.3450 mL
40 mM 0.0704 mL 0.3518 mL 0.7035 mL 1.7588 mL
50 mM 0.0563 mL 0.2814 mL 0.5628 mL 1.4070 mL
60 mM 0.0469 mL 0.2345 mL 0.4690 mL 1.1725 mL
80 mM 0.0352 mL 0.1759 mL 0.3518 mL 0.8794 mL
100 mM 0.0281 mL 0.1407 mL 0.2814 mL 0.7035 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Vidofludimus Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Vidofludimus717824-30-14sc-101 SC12267SC12267SC 12267SC-12267Dihydroorotate DehydrogenaseInterleukin RelatedFXRDHODHILNR1H4oralnon-alcoholic fatty liver disease (NAFLD)dihydroorotate dehydrogenase (DHODH)farnesoid X receptor (FXR)immunomodulatoryinflammatory bowel disease (IBD)fatty liverInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Vidofludimus
Cat. No.:
HY-14908
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.